PTC’s Sephience Launch Appears Off To A Strong Start
PTC's new drug, Sephience, is showing strong initial sales performance. The company anticipates blockbuster status for the drug, based on its first five months of revenue. This success indicates a promising start for Sephience in the market.
AMICUS THERAPEUTICS, INC. SEC 10-K Report
Amicus Therapeutics, Inc. has released its annual Form 10-K report, detailing significant financial growth with net product sales of $634.2 million and a reduced net loss, driven by the strong performance of Galafold® and Pombiliti® + Opfolda®. The report highlights strategic initiatives including new product launches, pipeline expansion through licensing DMX-200, and a pending merger with BioMarin Pharmaceutical Inc. The company also addresses key challenges and risks, such as the BioMarin transaction, reliance on key products, and regulatory and market risks.
Botulinum Toxins Market Size & Growth Forecast to 2030
The global botulinum toxins market is projected to reach USD 15.72 billion by 2030, growing at a CAGR of 12.0% from USD 8.92 billion in 2025, driven by increasing aesthetic consciousness and expanding therapeutic applications. Key players include AbbVie, Ipsen, and Galderma, with significant market share in North America, while the Asia Pacific region is expected to show the highest growth. The market is influenced by a shift towards minimally invasive procedures, biosimilar competition, and product innovation.
Barclays Initiates Coverage of Biogen (BIIB) with Equal-Weight Recommendation
Barclays has initiated coverage of Biogen (BIIB) with an Equal-Weight recommendation. The average one-year price target for Biogen is $195.32/share, suggesting a 1.69% upside from its latest closing price. Institutional ownership in Biogen shows a bullish outlook, with a put/call ratio of 0.75, and total shares owned by institutions increased by 2.95% in the last three months.
Biogen (BIIB) Receives New Analyst Coverage with Equal-Weight Ra
Barclays has initiated coverage on Biogen (BIIB) with an Equal-Weight rating and set a new price target of $185.00. This follows recent analyst adjustments from other firms, with ratings ranging from Neutral to Buy and price targets showing upward revisions. The average target price from 31 analysts for Biogen is $205.46, suggesting a 7.14% upside from its current price, and the stock holds an "Outperform" status based on consensus recommendations.
Persistent Asset Partners Ltd Sells 71,539 Shares of TG Therapeutics, Inc. $TGTX
Persistent Asset Partners Ltd significantly reduced its stake in TG Therapeutics, Inc. ($TGTX) by selling 71,539 shares, decreasing their holdings by 83.6% to 14,041 shares valued at $507,000. Other institutional investors like Public Sector Pension Investment Board and Jump Financial LLC either increased their positions or initiated new ones. The article also covers the company's stock performance, insider trading activity, and recent analyst ratings, which currently average a "Moderate Buy" with a consensus price target of $50.00.
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More
The global stem cell and regenerative therapy market is projected to grow significantly from $16.7 billion in 2025 to $43.8 billion by 2030, driven by technological advancements and increased investments. This growth is fueled by the potential of these therapies to address various chronic health conditions such as cancer, Parkinson's, and diabetes. The market report provides a comprehensive analysis of trends, revenue forecasts, segmentation, and profiles of leading companies like Gilead Sciences, Novartis, and Bristol-Myers Squibb.
Strong Analyst Confidence in C4 Therapeutics (CCCC)’s Cemsidomide Drives 270% Upside Potential
Analysts are highly confident in C4 Therapeutics (NASDAQ: CCCC) and its primary degrader, Cemsidomide, predicting a 270.37% upside potential for the stock. The company has outlined key clinical and regulatory milestones through 2028, targeting accelerated approval for Cemsidomide in relapsed/refractory multiple myeloma and planning significant trial advancements. C4 Therapeutics is also leveraging partnerships with major pharmaceutical companies to expand its pipeline beyond oncology.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stock Position in Biogen Inc. $BIIB
BNP PARIBAS ASSET MANAGEMENT Holding S.A. significantly increased its stake in Biogen Inc. by 20.3% in the third quarter of 2026, now holding 196,903 shares valued at approximately $27.58 million. This comes as Biogen reported strong Q4 earnings, surpassing analyst estimates, and provided FY 2026 guidance. While institutional investment in Biogen remains high, company insider Priya Singhal recently reduced her holdings, and analysts currently hold a mixed "Hold" consensus rating for the stock.
Palatin to test 2 obesity-targeting drugs for PWS in clinical trials this year
Palatin Technologies plans to advance two experimental obesity-targeting drugs, PL7737 and a long-acting peptide, into clinical trials this year for people with Prader-Willi syndrome (PWS) and hypothalamic obesity. These drugs are designed to activate the melanocortin-4 receptor (MC4R) to suppress hunger and are aimed at improving patient tolerability by reducing gastrointestinal side effects and hyperpigmentation, a known side effect of current MC4R agonists. The company expects to submit investigational new drug applications and initiate Phase 1 trials for both candidates in 2026.
Eisai & Biogen Canada Disagree With Canada's Drug Agency's Leqembi Reimbursement Rejection
Eisai and Biogen Canada have expressed disagreement with Canada's drug agency's decision to reject reimbursement for their drug Leqembi. The news, reported by Reuters and Refinitiv, indicates a dispute over the drug's availability through public reimbursement in Canada.
New Biogen Chair Freire May Recast Partnerships And Capital Priorities
Biogen has appointed Dr. Maria C. Freire as the new Chair of its Board of Directors, a move that could significantly influence the company's future partnerships, capital allocation, and R&D strategies. Dr. Freire's extensive background in biomedical research and public-private partnerships comes at a time when Biogen reported a quarterly net loss and a lower full-year net income compared to the previous year. Investors will be watching how her leadership impacts Biogen's existing pipeline, patient-centric outcomes, and engagement with regulators.
Biogen (BIIB) Valuation Check After Earnings Momentum And Analyst Optimism
Biogen (BIIB) has seen significant share price momentum following strong quarterly earnings and analyst optimism regarding its product portfolio, with a 30-day return of 18.07% and a one-year return of 42.03%. Despite this, Simply Wall St's analysis suggests the stock is currently slightly overvalued by about 2.4% with a fair value pegged around $190, compared to its last close of $194.13. However, when looking at traditional multiples, its P/E ratio of 22x suggests it's comparatively cheaper than peers, leading to a mixed valuation outlook.
NEOS Investment Management LLC Boosts Position in Biogen Inc. $BIIB
NEOS Investment Management LLC significantly increased its stake in Biogen Inc. (NASDAQ:BIIB) by 55.7% in the third quarter, holding shares valued at approximately $8.03 million. This increase follows Biogen's exceeding quarterly earnings expectations with $1.99 EPS and $2.28 billion in revenue, leading to a reaffirmed FY2026 guidance. The stock currently trades around $194, and analysts generally rate it as a "Hold" with an average target price of $205.84, despite mixed institutional investor activity.
7 Most Volatile Stocks Under $5 for Day Trading
The article identifies C4 Therapeutics, Inc. (NASDAQ:CCCC) as one of the most volatile stocks under $5 suitable for day trading. Analysts are bullish on CCCC, projecting a significant upside due to its primary degrader, Cemsidomide, which is progressing through clinical trials. The company has several key clinical and regulatory milestones planned through 2028, including an NDA submission target and multiple phase trials for its oncology and other programs.
Novartis/Unnatural Team Up On Macrocyclic Peptides
Novartis has partnered with Unnatural Products to collaborate on the development of macrocyclic peptides. This collaboration aims to leverage the expertise of both companies in drug discovery. The article was published on February 18, 2026.
Inside Satellos’ experimental DMD pill at live online event
Satellos Bioscience will host a virtual Key Opinion Leader (KOL) event on February 24, 2026, focused on its experimental Duchenne Muscular Dystrophy (DMD) therapy, SAT-3247. Dr. Kevin M. Flanigan will join company management to discuss DMD and review SAT-3247's progress, including results from Phase 1a/b trials and updates on ongoing Phase 2 pediatric studies. SAT-3247 is an oral small molecule designed to restore natural muscle repair by targeting the AAK1 protein, aiming to develop a treatment independent of dystrophin and exon mutation status.
BridgeBio earnings up next: Can pipeline wins fuel growth?
BridgeBio Pharma Inc. is set to release its Q4 and full-year 2025 earnings, with analysts expecting a significant improvement in financials and maintaining a "strong buy" rating for the stock. Investors will focus on the commercial performance of Attruby, progress in the pipeline with drugs like infigratinib for achondroplasia, and the company's operating leverage and cash runway as it aims for profitability. The report will assess if BridgeBio's decentralized drug development model can lead to scalable and profitable growth, potentially positioning it as a major biotech player.
Truist Financial Keeps Their Hold Rating on Advance Auto Parts (AAP)
Truist Financial has maintained a Hold rating on Advance Auto Parts (AAP) with a price target of $57.00, following a report from analyst Scot Ciccarelli. This rating comes despite the company reporting quarterly revenue of $1.97 billion and a net profit of $6 million in its latest earnings, compared to a net loss in the previous year. Other analysts have offered mixed ratings, with some reiterating a Sell while others have raised price targets.
Wegovy copycat to be priced competitively with 50-60% discounts: Dr Reddy's
Indian drugmaker Dr Reddy's Laboratories plans to launch a generic version of Novo Nordisk's weight-loss drug Wegovy at a price 50-60% lower than the branded product. The company aims to leverage the upcoming patent expiry for semaglutide in March and its recent approval for a generic Ozempic, targeting 12 million injectable pens in the first year. This move positions India as a key battleground for the expanding global weight-loss drug market.
Biogen head of pharm ops Murphy buys $585 in stock
Nicole Murphy, Biogen's Head of Pharmaceutical Operations and Technology, recently purchased 3 shares of the company's common stock for $585. This transaction indicates insider confidence, especially as Biogen's stock shows strong momentum and is considered undervalued by InvestingPro analysis despite trading near its 52-week high. Analysts hold a moderate buy consensus for Biogen, reinforced by strong recent financial performance that exceeded expectations.
Uveitis Clinical Trial Pipeline Expands as 15+ Companies
The Uveitis clinical trial pipeline is expanding with over 15 companies advancing more than 15 therapies toward market entry, according to a DelveInsight report. Key developments include FDA clearances for new drugs like NOV05 and expanded indications for existing ones such as YUFLYMA and ILUVIEN. Promising therapies like Tarsier Pharma's TRS01 and Eyevensys' EYS606 are highlighted, targeting various mechanisms of ocular inflammation.
Friedreich’s Ataxia Clinical Trial Pipeline Expands as 10+ Companies Progress 10+ Novel Therapies Toward Market Entry, Finds DelveInsight | PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx
DelveInsight's report indicates that over 10 companies are developing more than 10 novel therapies for Friedreich’s Ataxia, with several drugs, such as LX2006, RT001, and Leriglitazone (MIN-102), progressing through clinical stages. LX2006 received Breakthrough Therapy designation from the FDA, and its developers plan a pivotal study in the first half of 2026. This expansion reflects significant activity in addressing the unmet medical needs for Friedreich's Ataxia.
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Biogen Inc. (NASDAQ:BIIB)
Representative Gilbert Ray Cisneros, Jr. recently disclosed a purchase of $1,001–$15,000 in Biogen Inc. (NASDAQ:BIIIB) shares on January 30th. This transaction was part of a series of stock purchases by the Representative across various companies. Biogen recently exceeded earnings expectations, reporting an EPS of $1.99 against an estimated $1.61 and provided optimistic FY2026 guidance.
Landmark eye trial: two-thirds on AXPAXLI kept vision at 1 year
Ocular Therapeutix reported positive topline results for its AXPAXLI (OTX-TKI) in the SOL-1 Phase 3 superiority trial for wet AMD. The trial successfully met its FDA-aligned primary endpoint at Week 36, demonstrating that 74.1% of subjects maintained vision, and showed durable Week 52 outcomes with 65.9% maintaining vision, surpassing aflibercept. Despite these strong clinical results, the market reacted negatively, with Ocular Therapeutix (NASDAQ: OCUL) stock declining by 21.28% on the news day.
Dr Reddy's aims to launch generic obesity drug at 60% discount
Dr Reddy's Laboratories plans to launch a generic version of Novo Nordisk's weight-loss drug Wegovy in India at a price up to 60% lower than the branded product. This move follows the patent expiry for semaglutide in March, opening the Indian market for generic drugmakers. The company aims to sell 12 million injectable semaglutide pens in the first year and is also working on a biosimilar version of the cancer therapy rituximab for the U.S. market.
Dr Reddy’s says Wegovy copycat to be priced competitively, with 50–60% discounts feasible
Indian drugmaker Dr Reddy's Laboratories plans to launch a generic version of Novo Nordisk's weight-loss drug Wegovy in India at a significantly lower price, potentially 50-60% cheaper than the original. This move is timed with the patent expiration for semaglutide in March, intensifying competition in India's rapidly growing weight-loss drug market, which analysts project to be worth $150 billion annually by the decade's end. Dr Reddy's has already received approval for a generic Ozempic and expects approval for Wegovy, aiming to sell 12 million injectable pens in the first year.
5,611 Shares in Biogen Inc. $BIIB Purchased by Caprock Group LLC
Caprock Group LLC has acquired a new stake of 5,611 shares in Biogen Inc. (NASDAQ:BIIB), valued at approximately $742,000, according to its latest 13F filing. Biogen recently surpassed quarterly earnings estimates with an EPS of $1.99 and revenue of $2.28 billion, and has issued FY 2026 guidance implying an EPS of 15.250-16.250. Institutional investors hold a significant portion of Biogen's stock, 87.93%, with analyst ratings generally advising "Hold" and an average price target of $205.84.
Why Vertex Pharmaceuticals (VRTX) Is Up 6.0% After Profit Rebound And Non-CF Pipeline Update - And What's Next
Vertex Pharmaceuticals reported strong full-year 2025 results with a revenue increase to US$12.00 billion and a significant rebound to a US$3.95 billion net profit. The company's 2026 guidance anticipates growing contributions from non-cystic fibrosis products like CASGEVY and JOURNAVX, alongside a new collaboration in autoimmune diseases. This shift towards non-CF revenue and improved profitability is reshaping Vertex's investment narrative and risk profile.
What Are Wall Street Analysts' Target Price for Biogen Stock?
Barchart.com analyzes Biogen Inc.'s (BIIB) stock performance, noting its substantial outperformance against the S&P 500 Index and the iShares Biotechnology ETF over the past year. The article highlights strong Q4 fiscal 2025 financial results driven by new product growth and discusses analyst ratings, with a "Moderate Buy" consensus and a mean price target suggesting potential upside.
AlphaQuest LLC Sells 10,789 Shares of Biogen Inc. $BIIB
AlphaQuest LLC significantly reduced its holdings in Biogen Inc. by 96.6%, selling 10,789 shares to finish with 375 shares valued at $53,000. This comes as Biogen reported a quarterly EPS beat but a 7.2% year-over-year revenue decline, setting its FY2026 EPS guidance between 15.250 and 16.250. Analyst ratings for Biogen are mixed, with a consensus "Hold" rating and an average price target of $205.84.
Early Diagnosis Kit for Alzheimer's Disease Market Outlook
Coherent Market Insights has published a new report detailing the "Early Diagnosis Kit for Alzheimer's Disease Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033". The report extensively covers market competition, geographic distribution, growth potential, success factors, risk assessment, and financial analysis. It also identifies major market players such as Eli Lilly, Biogen, Roche, and Abbott Laboratories, and segments the market by diagnostic methods.
Renee Gala Outlines Jazz Pharmaceuticals Vision And Pipeline Priorities For Investors
Jazz Pharmaceuticals CEO Renee Gala has presented a refreshed long-term vision emphasizing growth and research focus, particularly on prioritizing the development pipeline. This strategic outline aims to guide future product development across neurology, oncology, and cannabinoid therapies. Investors are encouraged to watch how this vision aligns with upcoming financial guidance and impacts resource allocation, especially given the company's concentrated portfolio and elevated implied volatility in its stock.
Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit
Stoke Therapeutics presented long-term data for its Dravet syndrome program, showing durable seizure reductions and cognitive improvements, and outlined the design of its ongoing EMPEROR Phase 3 trial. The company also announced the initiation of a new Phase I/II dose-escalation program for autosomal dominant optic atrophy (ADOA). Stoke Therapeutics ended 2025 with $400 million in cash, providing a runway into 2028.
Rhumbline Advisers Has $40.51 Million Position in Biogen Inc. $BIIB
Rhumbline Advisers reduced its stake in Biogen Inc. by 3.6% in the third quarter, now holding 289,206 shares valued at $40.51 million. Despite a 7.2% year-over-year revenue decline, Biogen surpassed quarterly earnings estimates and provided optimistic FY2026 guidance. Institutional ownership remains high at 87.93%, with several major investment firms adjusting their positions, and analysts have issued various ratings for the stock.
Is Vertex Pharmaceuticals (VRTX) Still Attractive After Strong Multi Year Share Price Gains
Vertex Pharmaceuticals (VRTX) has seen significant share price gains over multiple years, prompting a valuation analysis. Simply Wall St's Discounted Cash Flow model suggests the stock is undervalued by 36.0% at its current price of US$491.47, with an intrinsic value of about $767.46 per share. However, its P/E ratio of 31.54x is higher than the biotech industry average, screening it as somewhat overvalued by that metric.
Renee Gala Outlines Jazz Pharmaceuticals Vision And Pipeline Priorities For Investors
Jazz Pharmaceuticals CEO Renee Gala has presented a refreshed long-term vision emphasizing pipeline development and resource allocation in neurology and oncology. This strategic outline is crucial for investors as it details the company's future product development and patient impact beyond typical quarterly updates. The market is already showing heightened interest, with high implied volatility in options ahead of upcoming results, making Gala's clear vision important for investor confidence and assessing potential risks and rewards.
Biogen’s New Therapies Surpass US$1 Billion In Sales Might Change The Case For Investing In BIIB
Biogen's Q4 2025 results showed that newer therapies like Leqembi, Skyclarys, Xerxuve, and Calcadi collectively generated over US$1 billion in 2025 revenue, despite a quarterly net loss and lower annual earnings. This performance, along with the appointment of Dr. Maria Freire as incoming Chair, is seen as crucial for Biogen's investment narrative, as the company increasingly relies on its emerging neurology portfolio to offset pressures in legacy products. While the company faces competitive challenges, its future hinges on the success of these new launches and strategic leadership in a dense period of clinical and regulatory events.
TG Therapeutics, Inc. $TGTX Shares Bought by Public Sector Pension Investment Board
Public Sector Pension Investment Board significantly increased its stake in TG Therapeutics (NASDAQ:TGTX) by 14.5%, now holding 529,271 shares valued at approximately $19.12 million. Several other institutional investors also boosted their positions, contributing to an overall institutional ownership of 58.58%. While analysts maintain a "Moderate Buy" consensus rating with a $50 price target, a director recently sold 5,000 shares, reducing their personal stake.
Illinois Municipal Retirement Fund Reduces Holdings in Coterra Energy Inc. $CTRA
The Illinois Municipal Retirement Fund significantly cut its stake in Coterra Energy Inc. (NYSE:CTRA) by 19% in the third quarter, selling 68,900 shares and ending with 293,569 shares valued at approximately $6.94 million. Despite this reduction, other large institutional investors, such as Vanguard Group Inc., increased their positions, and collective institutional ownership stands at nearly 88%. Coterra Energy is trading near its 52-week high with a "Moderate Buy" consensus rating and an average price target of $33.48.
LSV Asset Management Grows Position in Biogen Inc. $BIIB
LSV Asset Management significantly increased its stake in Biogen Inc. by 21.8% during the third quarter, now owning 306,839 shares valued at over $42 million. Other institutional investors like Vanguard Group, State Street Corp, and Geode Capital Management also boosted their positions. This comes as Biogen's stock performance shows a 50-day moving average of $178.22 and a two-hundred day moving average of $158.85, with several analysts maintaining "buy" or "outperform" ratings.
Oppenheimer & Co. Inc. Has $1.91 Million Stock Position in Biogen Inc. $BIIB
Oppenheimer & Co. Inc. significantly increased its stake in Biogen Inc. by 501.1% in Q3, now holding 13,610 shares valued at approximately $1.91 million. The firm has also raised its price target for Biogen to $225 with an "outperform" rating. Biogen recently exceeded quarterly earnings expectations with an EPS of $1.99 and revenue of $2.28 billion, and has provided strong FY2026 guidance.
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages
TG Therapeutics, Inc. (NASDAQ:TGTX) has received an average rating of "Moderate Buy" from six brokerages, with an average one-year target price of $50.00. Insider transactions show Director Yann Echelard selling 5,000 shares in November, while institutional investors hold 58.58% of the company's stock. The company's shares opened at $28.50, with a market capitalization of $4.52 billion and a P/E ratio of 10.25.
Assessing Travere Therapeutics (TVTX) Valuation After Recent Share Price Weakness And FILSPARI Growth Hopes
Travere Therapeutics (TVTX) shares have experienced recent weakness, but analysts suggest the stock is undervalued, with a fair value pegged at $41.64 compared to its current price of $27.82. This valuation heavily relies on the anticipated label expansion of its drug FILSPARI to treat FSGS, a rare kidney disease, which would give Travere a first-mover advantage and a new, high-margin revenue stream. However, the valuation's dependence on FILSPARI's success and potential FDA delays or weaker-than-expected uptake pose significant risks.
Loar (NYSE:LOAR) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Loar (NYSE:LOAR) stock rating from "hold" to "buy" on Saturday, with the company currently holding an overall analyst consensus of "Buy" and a consensus price target of $90.25. Loar also beat quarterly EPS estimates ($0.35 vs. $0.22) with a 22.5% increase in year-over-year revenue to $126.75M. Despite a relatively high valuation with a PE ratio of 97.73, various institutional investors have adjusted their stakes in Loar.
Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs
Lyell Immunopharma has initiated a Phase 3 trial for its experimental CAR-T therapy, ronde-cel, directly comparing it against existing marketed treatments for large B-cell lymphoma. Concurrently, a new European Life Sciences Coalition has launched to address the funding gap for biotech startups in Europe. Additionally, Novocure received FDA approval for its Optune Pax device for pancreatic cancer, and Biogen announced a change in its board chair, with Maria Freire succeeding Caroline Dorsa.
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 - Here's Why
Wedbush has increased its price target on Biogen Inc. (BIIB) to $187 from $178, maintaining a Neutral rating, after the company reported strong Q4 and full-year 2025 financial results. RBC Capital also raised its price target to $233 with an Outperform rating, citing stability and a solid foundation for future growth. BMO Capital similarly adjusted its price target to $196 and maintained a Market Perform rating following Biogen's earnings beat.
Sanofi’s stunning CEO switch—Chutes & Ladders
Sanofi is replacing CEO Paul Hudson with Merck KGaA leader Belén Garijo after a series of R&D setbacks. Hudson's departure follows a six-year tenure marked by challenges, with Garijo set to take over in April after an interim period. This leadership change comes amidst similar executive shuffles at CSL and Helus Pharma, detailed in this week's "Chutes & Ladders" column, which also highlights other significant hirings and promotions across the biopharma industry.
Sarepta’s SRP-1005 Trial Approval Opens New Huntington’s Disease Opportunity
Sarepta Therapeutics received Medsafe approval in New Zealand for a first-in-human clinical trial of SRP-1005, an investigational siRNA therapeutic for Huntington's Disease. This marks Sarepta's entry into Huntington's Disease research, broadening its rare disease focus beyond Duchenne muscular dystrophy. The Phase 1 study primarily aims to assess safety and dosing, creating a new clinical catalyst for the company and showcasing its genetic medicine expertise in an area with limited treatment options.
BIIB: Late-stage lupus therapies and a diverse immunology pipeline target major unmet needs
Biogen (BIIB) presented a strong immunology pipeline at a recent symposium, featuring promising late-stage lupus therapies with new mechanisms and trial designs. The company is focusing on unmet needs in SLE and CLE, while also developing early-stage programs in neuroinflammation and MS, indicating a multi-indication strategy for future growth. This information is based on an AI-generated summary of Biogen's Piper Sandler Virtual Novel Targets in Immunology Symposium Audio Transcript.
